© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Anika Therapeutics, Inc. (ANIK) stock surged +1.25%, trading at $21.10 on NASDAQ, up from the previous close of $20.84. The stock opened at $21.10, fluctuating between $20.94 and $21.40 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | 20.95 | 21.44 | 20.80 | 21.10 | 98.94K |
| Aug 27, 2026 | 21.51 | 21.97 | 20.80 | 20.84 | 171.47K |
| Aug 26, 2026 | 21.29 | 21.80 | 20.85 | 21.68 | 89.48K |
| Aug 25, 2026 | 21.43 | 21.92 | 21.35 | 21.40 | 73.46K |
| Aug 24, 2026 | 22.35 | 22.53 | 21.13 | 21.34 | 124.71K |
| Aug 21, 2026 | 21.38 | 22.32 | 21.01 | 21.78 | 340.39K |
| Aug 20, 2026 | 21.15 | 21.65 | 21.10 | 21.34 | 89.34K |
| Aug 19, 2026 | 21.88 | 22.05 | 21.25 | 21.26 | 80.21K |
| Aug 18, 2026 | 21.48 | 21.98 | 21.09 | 21.57 | 86.93K |
| Aug 17, 2026 | 21.21 | 21.99 | 20.74 | 21.47 | 121.2K |
| Aug 14, 2026 | 21.17 | 21.98 | 21.04 | 21.50 | 124.94K |
| Aug 13, 2026 | 22.05 | 22.42 | 21.04 | 21.17 | 102.07K |
| Aug 12, 2026 | 21.23 | 22.23 | 20.42 | 22.03 | 140.98K |
| Aug 11, 2026 | 20.59 | 21.64 | 20.54 | 21.23 | 114.21K |
| Aug 10, 2026 | 21.93 | 22.88 | 20.61 | 20.68 | 125.99K |
| Aug 07, 2026 | 20.60 | 21.55 | 20.09 | 21.42 | 183.51K |
| Aug 06, 2026 | 19.40 | 20.39 | 19.40 | 20.16 | 193.06K |
| Aug 05, 2026 | 19.64 | 19.68 | 19.00 | 19.19 | 95.16K |
| Aug 04, 2026 | 20.57 | 20.75 | 18.98 | 19.61 | 238.7K |
| Aug 03, 2026 | 19.59 | 21.11 | 19.59 | 20.74 | 182.03K |
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
| Employees | 235 |
| Beta | 0.19 |
| Sales or Revenue | $166.66M |
| 5Y Sales Change% | 0.556% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Specialties |